{"title":"[Effect of apigenin on dendritic cells maturation and function in murine splenocytes].","authors":"Yi-fei Liu, Xiao-xu Xue, Zheng-yi Li, Jun-peng Wang, Yi-jie Zhang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>This study was designed to explore the effect of apigenin (Api) on dendritic cell (DCs) maturation\nand function in murine spleen cells. The single spleen cell was isolated, and then cultured with lipopolysaccharide\n(LPS) in the present and absence of apigenin. After 24 h, the toxicity of Api and the T cell proliferation were\ndetermined by CCK8 kit. In addition, we collected the cell-free supernatants to measure cytokine production\nusing ELISA, collected the cells to determine the DC maturation using flow cytometry. Finally, we purified\nApi and/or LPS-treated CD11c+ DCs which were pulsed with ovalbumin (OVA)323−339 and then were adoptive\ntransferred into C57BL/6 mice to detect the OVA323−339-specific T cell proliferation and T helper (Th1) and Th2\ncell secreting IFN-γ and IL-4 production, respectively. We found that Api did not affect splenocyte viability, but\ninhibited the production of pro-inflammatory cytokine IL-1β, IL-6 and TNF-α, not anti-inflammatory cytokine\nIL-10. In addition, Api inhibited the expression of co-stimulatory CD80, CD86 and MHCII of CD11c + DCs.\nFinally, compared to LPS+OVA DCs group, DCs from Api and LPS co-treated splenocytes (Api+LPS+DCs)\nimpaired OVA323−339-specific T cell proliferation and the production of IFN-γ and IL-4 in CD4+ T cells, which\nhad the similar responses with OVA+DCs. These data suggest that Api exhibits anti-inflammatory properties\nvia inhibiting DC activation and function, as a new immune-modulator, which may induce immune-tolerance\nwith a benefit to those with chronic inflammation.</p>","PeriodicalId":35924,"journal":{"name":"药学学报","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"药学学报","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This study was designed to explore the effect of apigenin (Api) on dendritic cell (DCs) maturation
and function in murine spleen cells. The single spleen cell was isolated, and then cultured with lipopolysaccharide
(LPS) in the present and absence of apigenin. After 24 h, the toxicity of Api and the T cell proliferation were
determined by CCK8 kit. In addition, we collected the cell-free supernatants to measure cytokine production
using ELISA, collected the cells to determine the DC maturation using flow cytometry. Finally, we purified
Api and/or LPS-treated CD11c+ DCs which were pulsed with ovalbumin (OVA)323−339 and then were adoptive
transferred into C57BL/6 mice to detect the OVA323−339-specific T cell proliferation and T helper (Th1) and Th2
cell secreting IFN-γ and IL-4 production, respectively. We found that Api did not affect splenocyte viability, but
inhibited the production of pro-inflammatory cytokine IL-1β, IL-6 and TNF-α, not anti-inflammatory cytokine
IL-10. In addition, Api inhibited the expression of co-stimulatory CD80, CD86 and MHCII of CD11c + DCs.
Finally, compared to LPS+OVA DCs group, DCs from Api and LPS co-treated splenocytes (Api+LPS+DCs)
impaired OVA323−339-specific T cell proliferation and the production of IFN-γ and IL-4 in CD4+ T cells, which
had the similar responses with OVA+DCs. These data suggest that Api exhibits anti-inflammatory properties
via inhibiting DC activation and function, as a new immune-modulator, which may induce immune-tolerance
with a benefit to those with chronic inflammation.
药学学报Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.20
自引率
0.00%
发文量
0
期刊介绍:
Acta Pharmaceutica Sinica B (APSB) is a bimonthly English peer-reviewed online journal in ScienceDirect, which publishes significant original research articles, communications and high quality reviews of recent advances. APSB encourages submissions from all areas of pharmaceutical sciences, including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.
APSB is a part of the series Acta Pharmaceutica Sinica, which was founded in 1953. The journal is co-published by Elsevier B.V., in association with the Institute of MateriaMedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.